Canexis Pharma at CPHI Milan 2026: Swiss EU-GMP cannabinoid APIs
Canexis Pharma AG in Schlattingen, Canton of Thurgau: EU-GMP production site for cannabis-based APIs, Hauptstrasse 25, Switzerland
Swiss cannabis API manufacturer Canexis Pharma AG exhibits at CPHI Milan, 6–8 October 2026, at stand 2D98 in the Natural Extracts zone – presenting Cannabidiol Ph. Eur., Dronabinol (USP/DAC), THCA and GMP cannabis extracts and distillates, all manufactured in Switzerland under EU-GMP Part I and Part II licences.
Schlattingen, Switzerland – Canexis Pharma AG, a Swiss manufacturer of cannabis-based active pharmaceutical ingredients, will exhibit at CPHI Milan 2026 from 6 to 8 October at Fiera Milano. Visitors will find the company at stand 2D98 in the Natural Extracts zone.
Canexis presents its complete EU-GMP portfolio: Cannabidiol Ph. Eur. as a white crystalline pure API, Dronabinol (USP/DAC) with an assay of at least 95 % Δ9-THC, THCA, THC- and CBD-dominant cannabis extracts and distillates, and standardized cannabis extracts with custom THC/CBD ratios for compounding and bulk medicinal products. All products are manufactured in Switzerland under EU-GMP Part I and Part II licences, a Swissmedic manufacturing licence and a Swiss narcotics licence, and are available in bulk from 100 g to 25 kg.
"CPHI Milan is the place where we meet the pharmaceutical development teams, compounding pharmacies and finished-product manufacturers who need a reliable, fully documented cannabinoid API source in Europe," says Adriano Meier, Co-Founder of Canexis Pharma AG. "We look forward to discussing specifications, samples and supply agreements at our stand."
The Canexis team is available for meetings throughout the show. Appointments can be booked in advance via the CPHI Event Planner or by e-mail to [email protected]. The product flyer is attached to this article; the full product catalogue with key specifications, pack sizes and regulatory status is available on request at www.canexis.com.
About Canexis Pharma AG
Founded in 2020, Canexis Pharma AG extracts, refines and purifies cannabinoids from GACP-grown cannabis into pharmaceutical-grade bulk APIs at its site in the Canton of Thurgau. The validated process chain covers extraction, decarboxylation, two-stage short-path distillation and crystallisation with a capacity of approximately 1,000 kg of biomass per day. Canexis supplies partners in regulated markets across Europe, APAC, LATAM and Africa. www.canexis.com
